Karyopharm to Host Investor Conference Call Featuring Expert Perspectives on the Phase 3 SENTRY Trial in Myelofibrosis Following 2026 ASCO Presentation

– Event To Feature Dr. John Mascarenhas, Principal Investigator of the Phase 3 SENTRY Trial – – Conference Call Scheduled for Tuesday, June 2, 2026 at 2:00 p.m. ET – NEWTON, Mass., June 1, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical...

Read More